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Substantial genetic liability is shared across psychiatric disorders but less is known about risk 
variants that are specific to a given disorder. We used multi-trait conditional and joint 
analysis (mtCOJO) to adjust GWAS summary statistics of one disorder for the effects of 
genetically correlated traits to identify putative disorder-specific SNP associations. We 
applied mtCOJO to summary statistics for five psychiatric disorders from the Psychiatric 
Genomics Consortium – schizophrenia (SCZ), bipolar disorder (BIP), major depression 
(MD), attention-deficit hyperactivity disorder (ADHD) and autism (AUT). Most genome-
wide significant variants for these disorders had evidence of pleiotropy (i.e., impact on 
multiple psychiatric disorders) and hence have reduced mtCOJO conditional effect sizes. 
However, subsets of genome-wide significant variants had larger conditional effect sizes 
consistent with disorder-specific effects: 15 of 130 genome-wide significant variants for 
schizophrenia, 5 of 40 for major depression, 3 of 11 for ADHD and 1 of 2 for autism. We 
show that decreased expression of VPS29 in the brain may increase risk to SCZ only and 
increased expression of CSE1L is associated with SCZ and MD, but not with BIP. Likewise, 
decreased expression of PCDHA7 in the brain is linked to increased risk of MD but decreased 























Pervasive sharing of genetic risk factors between common psychiatric disorders (i.e. 
pleiotropy) has now been unequivocably demonstrated from genome-wide association studies 
(GWAS), as quantified by estimates of genetic correlation (rg) 1, 2. The rg estimates are 
highest between schizophrenia and bipolar disorder (0.67, standard error (s.e.) = 0.03) but are 
> 0.15 for any combination of the five common disorders of schizophrenia (SCZ), bipolar 
disorder (BIP), ADHD, Major Depression (MD) and autism spectrum disorders (AUT) 2, 3. 
Cross-diagnosis analyses can leverage power to identify genetic risk loci shared across 
classical diagnostic boundaries 4 and can increase power for risk prediction of disorders in 
independent samples 5, 6. The shared genetic basis for psychiatric disorders contributes to an 
evidence base supporting a trans-diagnostic approach in clinical practice 7. Nonetheless, 
traditional diagnostic classes reflect real symptom differences at patient presentation even 
though it can be difficult to classify some individuals given a high-degree of concurrent and 
longitudinal comordibity.  Since rg estimates are higher between data sets of the same 
disorder than between data sets of different disorders 4, 8 it implies some real biological basis 
to the classical diagnostic classes. Hence, a key question of importance in psychiatry is 
identification of genetic factors that are disorder specific rather than those shared across 
classical diagnostic groupings. Identifying such variants could aid in understanding the 
biological pathways that underlie the constellation of symptoms seen in each disorder.  
One method for identifying disorder-specific variants is to conduct a case-case 
GWAS with cases of one disorder compared to cases of another. The SCZ/BIP working 
group of the Psychiatric Genomics Consortium (PGC) conducted an association analysis 
comparing in logistic regression SCZ (N=23,585) vs BIP (N=15,270) cases to identify 
variants specific to each disorder. The cases were matched on ancestry and genotyping 
platform, hence the sample sizes were smaller than those available for the disorder specific 
GWAS which limits the statistical power. Conducting such analysis requires access to the 
raw genotypes which is not always feasible for all cohorts due to privacy laws. Methods that 
use summary statistics can utilise larger sample sizes without the need to provide access to 
raw daa to researchers. In addition, case-case GWAS can identify differences between pairs 
of disorders9, but does not generalize to the multivariate space to identify SNPs primarily 
associated one disorder.  
We conditioned the effect of SNPs estimated for one disorder on those of other 
disorders using multi-trait, conditional and joint analysis (mtCOJO)10, a summary-statistics 
based method that accounts for overlap in samples contributing to the disorder specific 
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GWAS. We report results from conditional analyses of 5 psychiatric disorders: SCZ, BIP, 
MD, ADHD and AUT using association summary statistics from meta-analyses conducted by 
the Psychiatric Genomics Consortium (PGC) including data from 23andMe. Each disorder is 
conditioned on the other four disorders in one model.  
 
Methods 
We applied the mtCOJO method as described in Zhu et al. 10. This method approximates a 
conditional analysis where the effect of a SNP on a disease is conditioned upon the covariates 
of the disease, but only requires summary statistics as input. As an example, if we are 
interested in estimating the effect of a SNP (z) on risk to schizophrenia (y) accounting for the 
effect of a covarying factor such as bipolar (x), we condition upon the effect of bipolar on 
schizophrenia  𝑏𝑏�𝑥𝑥𝑥𝑥, as estimated using Generalised Summary-based Mendelian 
Randomisation (GSMR). This can be extended to condition upon multiple covarying diseases 
so that the effect of the SNP on risk on the disorder of interest is estimated conditional upon 
the covariates on the disorder (see Supplementary Material for detailed description of the 
method).  
 
To identify independent genome-wide significant SNPs for use as genetic instruments in 
mtCOJO analysis, each dataset was clumped to select independent genome-wide significant 
(GWS) SNPs (p < 5 x 10-8) using 7,762 unrelated individuals from the Atherosclerosis Risk 
In Community (ARIC) dataset11, imputed to 1000Genomes Phase III as an LD reference 
sample. GWS SNPs more than 1MB apart or with an r2 value < 0.05 were considered to be 
independent. GSMR accounts for any remaining LD between instruments. GSMR analysis 
with filtering to remove SNPs with outlier pleiotropic effects (compared to other GWS SNPs) 
using the HEIDI test 12 was performed with each disorder included both as an exposure and 
an outcome in combination with the other disorders. Owing to having fewer than 10 
independent GWS SNPs, independent SNPs significant at p < 10-7 were used for GSMR 
analysis with autism as the exposure variable. In order to compare the estimated effects of 
one disorder on another from MR, we derived a conversion of the estimated effects from 
GSMR to the liability scale (see Supplementary Material, Supplementary Figure 1). 
 
We performed mtCOJO analysis (implemented in GCTA13  
(http://cnsgenomics.com/software/gcta/#mtCOJO) of 5 genetically correlated psychiatric 
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disorders using the results from large genome-wide association studies from the Psychiatric 
GWAS consortium (Table 1), running the analysis in turn with each disorder as the outcome 
with the other disorders as covariates. A total of 5,275,400 SNPs with matching alleles that 
were in common across the 5 disorders were used for further analysis. Indels were excluded 
from the analysis.  
 
For each disorder, SNP effects conditional upon the other disorders were calculated. Results 
were uploaded to FUMA for annotation 14. Ranking SNPs according to the difference 
between the marginal and conditional effect sizes for each disorder is not necessarily 
meaningful because, for example, a SNP that has a low estimated marginal effect, so no 
effect on the outcome trait, will have a large conditional effect if the SNP has a large effect 
on the covariate traits. For the purposes of identifying which SNPs show evidence of 
disorder-specificity, we focus on presenting results for SNPs that were GWS with the 
outcome disorder in the original GWAS. We further estimated whether the difference 
between the conditional and raw effect size of each SNP was significant (Supplementary 
Material).  
 
MAGMA gene-set analysis 
MAGMA gene-set analysis15 as implemented in FUMA was used to investigate which sets of 




LD-score regression 16 was used to estimate the genetic correlation between the conditional 
and unadjusted GWAS results. 
 
Summary Mendelian Randomisation  
To investigate the potential functional relevance of SNPs with disorder-specific effects, we 
applied the SMR approach 12, integrating eQTL (SNP-gene expression association) and 
mQTL (SNP_DNA methylation association) to the results from the conditional analyses. 
eQTL data from brain tissue were derived from a meta-analysis of the GTEx study, the 
Common Mind Consortium (CMC) and the Religious Orders Study and Memory and Aging 
Project (ROSMAP). The details of the meta-analysis have been described elsewhere17. Using 
meta-analysis results across brain tissues and studies is justified owing to the high correlation 
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in effect sizes between tissues17. Only genes with a cis-eQTL with peQTL < 5 x 10-8 were 
included in the analysis. Experiment-wide significance accounting for testing multiple SNPs 
across multiple traits was set at pSMR = 1.9 x 10-06 and the threshold for no evidence of 
heterogeneity due to pleiotropy at pHEIDI > 0.01. Individual-level genotypes from the ARIC 
data (n = 7,762 unrelated individuals) 11 were used to estimate LD for the HEIDI test. 
 To test for the effects of disorder-specific variants on DNA methylation, we used 
SMR to integrating trait association data with meta-analysed brain mQTL data set from Jaffe 
et al. (n = 526) ROSMAP (n = 486) and fetal brain mQTL data from Hannon et al 18. Only 
probes with at least one cis-mQTL with p < 5 x 10-8 were included in the SMR analysis. 
Probes that passed the significance threshold of 1.56 x 10-7 and did not show evidence of 
heterogeneity as indicated by the HEIDI test were considered to be significant. 
 
Cell-type specificity for disorders 
To gain insight into the cell types that are important for each disorder, we evaluated whether 
genes associated with specific brain cell-types are enriched for association with each of the 
disorders. Using data from single-cell sequencing experiments in mice, the cell-type 
specificity of each gene was calculated by comparing the expression of a gene in a given cell-
type to that across all cell types 19. MAGMA was used to calculate gene-based association 
statistics and to evaluate whether genes with high specificity in a given cell-type are enriched 
for association with a disorder. The enrichment analysis was performed for both unadjusted 
and conditional GWAS for all 5 disorders. To investigate whether there was a significant 
change in the cell-type enrichment after conditioning, MAGMA analysis was performed 
using the enrichment Z-scores from the unadjusted GWAS as covariates in the analysis and a 
conditional enrichment for all level 1 cell types analysed in Skene et al. 19 was estimated. 
 
Code Availability 




After merging GWAS summary statistics for the five psychiatric disorders 5,275,400 
autosomal SNPs remained (Table 1). The number of independent genome-wide significant 
SNPs annotated by FUMA 14 is much greater for SCZ (M =130) compared to the other 
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disorders (M =16, 40, 11, 2 for BIP, MD, ADHD, AUT respectively) reflecting mostly 
sample size, but also genetic architecture, and population risk. Linkage disequilibrium score 
regression (LDSC) estimates of SNP-based heritability on the liability scale and genetic 
correlations were all significantly different from zero (Table 2). Genetic correlations were 
highest between SCZ and BIP (rg = 0.67 (s.e. = 0.03)) and lowest between BIP and ADHD (rg 
= 0.15 (s.e. = 0.04)). The LD-score regression intercept was significantly greater than zero 
for the majority of pairs of disorders reflecting sample overlap in the GWAS studies. The 
intercept was highest between ADHD and AUT due to substantial overlap in controls. See 
Supplementary Material for discussion of interpretation of results in the context of sample 
overlap.   
 
The GSMR analyses highlights some asymmetries in the estimates of the causal effects of 
one disorder on another (Table 3). In particular, the estimated liability 𝑏𝑏�𝑥𝑥𝑥𝑥  when considering 
MD as an exposure for each trait is higher than the estimates in the reverse direction. One 
explanation is that since MD is so common and is frequently comorbid with other disorders 
that MD samples include those diagnosed and undiagnosed with other disorders. However, if 
model assumptions are violated it may have greater impact when there is a large difference in 
lifetime risk between the pairs of disorder. However, countering this, we find a higher 𝑏𝑏�𝑥𝑥𝑥𝑥 
from AUT to ADHD than from ADHD to AUT, but the standard errors on estimates are 
much higher for these disorders. Interpretation of these 𝑏𝑏�𝑥𝑥𝑥𝑥 estimates depends on the nature 
of the shared genetic contributions to psychiatric disorders that may reflect a complex mix of 
types of pleiotropy, where some sets shared of variants may have more correlated effect sizes 
than other sets of shared variants.  
 
Changes in Genetic Correlation  
The impact of the conditioning is demonstrated by the changes in the estimates of 𝑟𝑟𝑔𝑔�  
comparing original and conditional GWAS results. The 𝑟𝑟𝑔𝑔�  between SCZ conditional on the 
other disorders (denoted SCZcond) and SCZ remained high at 0.93, while between SCZcond and 
BIP it was much reduced (from 0.67 prior to conditioning to 0.36, after conditioning). It is 
noted that bzy is eliminated in the conditional analysis only if the SNP effect is mediated by 
trait x. Therefore, there is remaining genetic correlation because of pleiotropic SNP effects. A 
similar pattern of changes in genetic correlation with other traits was seen for the analyses 
with the other disorders as the outcome variable (Supplementary Table 1).  
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mtCOJO genome-wide significant SNP results 
As expected because of pleiotropy between disorders, conditional analysis leads to a 
reduction in the mean test statistic across all SNPs in the genome and hence the number of 
independent SNPs reaching the significance threshold (5x10-8) is reduced (Table 1). For each 
disorder, we present results for all independent SNPs significant in the unadjusted analysis or 
the conditional analysis (Supplementary Table 2). GWS SNPs that are more significantly 
associated in the conditional analysis than the unadjusted analysis are shown in Table 4. A 
larger conditional effect size suggests that these variants are disorder-specific or have 
heterogeneous effects across disorders.  
Given that SCZ is the disorder with the largest number of significant SNPs and for 
which the power to detect changes in effects is largest, we focus mostly on the results from 
the SCZ conditional analysis. Of the 130 SNPs from the unadjusted SCZ GWAS, five were 
more significant after adjusting for the other disorders (all of which had opposite direction of 
effects for BIP – Supplementary Table 2) and a further eight had a larger estimated effect 
size after conditioning. Forest plots for the four most significant SCZ SNPs from the 
conditional analysis (two of which were associated p<5x10-8 in the unadjusted analysis) are 
shown in Figure 1.  
For all disorders except for AUT, a number of SNPs surpass the significance 
threshold that were not significant in the original GWAS. For schizophrenia, ten SNPs that 
were significant in the conditional analysis and not in the original GWAS (Table 4). All 10 
SNPs have opposite effects for BIP, so that the allele that predisposes to SCZ is in the 
protective direction for BIP. Although these opposite effects could be due to ascertainment, 
among them are variants in or near genes with annotated biological functions that are 
potentially relevant for SCZ. For instance a  SNP that was significant in the conditional 
analysis (rs2973038 – padj = 1.28 x 10-08; pscz = 1.72 x 10-06 ) is located in the Glial Cell 
Derived Neurotrophic Factor (GDNF), a gene that encodes a protein that enhances the 
survival of midbrain dopaminergic neurons 20, and is expressed during development 21.  
All SNPs that were associated with BIP at p< 5x10-8 in the original GWAS were less 
significant in the conditional analysis, showing evidence that they have some pleiotropic 
effect across disorders. Notably, this includes genes involved in calcium signalling, 
dopaminergic signalling and synaptic plasticity, indicating these processes may be important 
across psychiatric disorders. Three SNPs that were not significant in the BIP GWAS were 
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significant in the conditional analysis (Table 4, Supplementary Table 2, Supplementary 
Figure 2).  
For each of the remaining disorders (MD, ADHD and AUT), we found that a small 
proportion of the existing significant SNPs had larger conditional effect sizes and one MD 
SNP and two ADHD SNPs that were not significant in the original GWAS became 
significant after conditioning (Table 4, Supplementary Table 2). However the difference in 
effect size after conditioning is not statistically significant for these SNPs, due to low 
statistical power (Supplementary Table 2). Forest plots for significant SNPs that had 
increased conditional effect sizes are shown in Supplementary Figures 3-5 
 
SMR analysis  
 Changes in the expression of 9 genes were significantly associated with the 5 
disorders (0 for BIP, 5 for SCZ, 3 for MD and 1 for ADHD, 0 for AUT) after conditioning 
and removal of genes in the MHC (Supplementary Tables 3-4), and a total of 72 DNA 
methylation sites (2 for BIP, 18 for SCZ, 37 for MD, 8 for ADHD, and 6 for AUT) were 
significantly associated with the 5 conditional traits (Supplementary Table 3-4).  
Significant SMR results for gene expression where the associated SNP is more 
significant in the conditional analysis are presented in Supplementary Table 3. Three out of 
5 significant SMR associations for SCZ were with SNPs where the conditional significance 
was greater than in the unadjusted analysis. One SNP - rs3759384 – is associated with 
decreased expression of VPS29 in the brain and significantly increased risk for SCZ in the 
unadjusted analysis and has a larger conditional effect size (Supplementary Figure 6), 
indicating that VPS29 may be linked to the development of SCZ and not other disorders. The 
VPS29 protein is a component of the retromer complex which prevents the degradation of 
certain proteins including signalling receptors, ion channels and small molecule transporters. 
The complex is essential for maintenance of neurons and has been implicated in the etiology 
of a number of neurodegenerative disorders 22.  
One of the three associations for MD was with a SNP (rs7732179) with greater 
significance in the conditional analysis. The same variant shows evidence of association with 
SCZ but with opposite directions of effect (bSCZ = -0.045; pSCZ = 1.7 x 10-6 and bBIP = -0.029; 
pBIP = 0.027). The A allele confers risk to MDD but is protective for SCZ and BIP 
(Supplementary Figure 7). The SNP is associated with expression of PCDHA7 in the brain. 
This gene encodes a member of the protocadherin family of genes located together on 
chromosome 5. A significant association was also found in this region in the DNA 
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methylation analysis of MD. Little is known about the exact function of these genes, however 
they are concentrated at the synaptic junction suggesting a key role in neuronal signalling 23.  
Out of 72 significant DNA methylation sites, 34 were associated with SNPs with 
higher significance in the conditional analyses (1 for BIP, 3 for SCZ, 21 for MD, 4 for 
ADHD and 5 for AUT) (Supplementary Table 3). It is noteworthy that one variant 
(rs2064853) was significantly associated with both SCZ and MD and DNA methylation near 
the CSE1L gene, but with opposite alleles increasing risk to each disorder (Supplementary 
Figure 8).  
 We investigated whether genes identified in the gene expression SMR or that are the 
closest gene to a significant methylation site are the primary target for FDA-approved drugs. 
We identified two genes that are targeted by medications. The serotonin receptor gene 
HTR1D which was identified in the DNA methylation analysis for MD is the primary target 
of the migraine drug naratriptan. Individuals with migraine are at 2-4 fold higher risk of 
developing depression and these results may suggest that triptans, used to treat migraines, 
could also be effective for MD.  
The second drug target identified is with MPL and ADHD. This gene is targeted by 
romiplostim, an orphan drug developed for treatment of chronic idiopathic thrombocytopenic 
purpura. 
 
MAGMA gene-set analyses 
We conducted MAGMA gene-set analysis in FUMA to identify pathways and gene-sets that 
are enriched for association with the disorders after conditional analyses and to identify 
which sets become more or less significant after conditioning. Results for each disorder are 
presented in Supplementary Table 5. After conservative Bonferroni correction for the 
number of gene-sets tested for each disorder, three gene sets were significant -  two for SCZ 
conditional analysis and one for AUT. For SCZ, the two significant sets were 
go:establishment of localization in the cell and GO:Dendrite, of which establishment of 
localization had a more significant p-value in the conditional analysis (Supplementary 
Table 5). For AUT, the gene-set GO:Dendrite_morphogenesis was significant after multiple 
testing and had a more significant p-value in the conditional analysis, potentially implicating 
genes expressed in dendrites in autism-specific pathology.   
 
Cell-type specificity for disorders  
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The results from the cell-type enrichment analyses of raw and conditional analyses are shown 
in Figure 2. Consistent with previous results, the original SCZ results were enriched in 
medium spiny neurons (MSNs), pyramidal CA1 cells, pyramidal SS1 cells, interneurons and 
serotonergic neurons (Supplementary Table 6). All of these cell types also show some 
evidence of association with BIP and to a lesser extent MD, consistent with the genetic 
correlation between disorders and hence show reduced enrichment in the SCZ conditional 
analysis. All enriched cell-types for SCZ remained significant after conditioning except for 
serotonergic neurons, indicating that genes specific to this cell-type may increase risk to all 
five disorders. Enrichment in interneurons was found for SCZ, BIP and MDD indicating their 
potential importance across all 3 disorders. After conditioning, this cell-type was still 
significantly enriched in SCZ and MDD, but not BIP. This may reflect that the sample size of 




Our goal was to identify genetic variants that show disorder specific association by 
conducting a summary statistics based GWAS analysis for each of five psychiatric disorders 
conditioning on GWAS results from the other disorders. As expected, given the high degree 
of pleiotropy across disorders, compared to original GWAS results the number of SNPs 
associated at the threshold of genome-wide significance is very much reduced for each 
conditional GWAS. We utilise mtCOJO as a method that uses summary statistics to quickly 
screen for SNP associations. Functional annotation can help prioritise the associations of 
most interest. It will be important to understand why a variant increases risk only to that 
disorder and not to others.  
By integrating conditional GWAS results with SNP-gene expression and SNP-
methylation results, we identify decreased expression of VPS29 as a potential biological 
mechanism underlying schizophrenia. The variant that increases risk to SCZ and is associated 
with decreased expression of VPS29 in brain tissue shows no evidence for association with 
other psychiatric disorders. The retromer complex, of which is VPS29 is a subunit, is highly 
conserved across eukaryotes. The complex plays a role in the recycling, delivery and 
degradation of proteins in the cell and is crucial in the maintenance of cell homeostasis24. 
Rare exonic mutations in members of the complex have been associated with Parkinson’s 
Disease and post-mortem studies have revealed decreased expression of all members of the 
complex in the brains of patients with Parkinson’s and Alzheimer’s disease. The expression 
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of all three members of the complex is linked such that decreasing expression of one leads to 
decreased expression of all of them. Knocking down VPS35 using siRNA leads to elevated 
generation of amyloid-beta and reduced synaptic transmission25, 26. There is therefore 
considerable interest in identifying pharmacological agents that prevent the degradation of 
the retromer complex as a therapeutic mechanism for neurodegenerative disease. Small 
molecule screens have identified potential therapeutic agents that have shown promise in 
vitro27. Our results provide that such compounds may of interest in targeting biological 
mechnisms specific to schizophrenia.    
Furthermore, SNPs associated with decreased expression of PCDH7 and decreased 
methylation near other members of the protocadherin gene family on chromosome 5 may 
increase risk of MD, but be protective for SCZ and BIP. The protocadherins are a large 
family of genes involved in cell-cell adhesion that are primarily expressed in the nervous 
system. They play a major role in the development of the nervous system and in regulating 
dendritic branching. The PCDHA7 gene is part of a complex cluster of protocadherin alpha 
genes in the same genomic locus. The expression of the different isoforms at the locus is 
controlled by upstream CpG sites. Owing to their functional role in nervous system 
development and their location in linkage peaks, the PCDHA genes have been investigated as 
candidate genes for bipolar and schizophrenia28. Moreover, an epigenetic study of concordant 
and discordant MZ twins for depression showed that affected twins had increased variation in 
methylation in the PCDHA region, highlighting instability in this region as a potential 
mechanism underlying depression29. Further studies of the role of the PCDHA gene cluster in 
psychopathology are warranted.   
Methylation in the promoter of the CSE1L gene, whose encoded protein influences 
cellular proliferation and has been linked to progression of a number of cancers, shows 
evidence of increasing risk to SCZ but being protective for MD.  
Consistent with the large degree of pleiotropy between disorders, we found that most 
of the significant biological pathways for each disorder had reduced significance after 
conditioning. Pathway analysis of conditional results identified a potential role for genes 
expressed in dendrites in both autism and schizophrenia. Likewise, for the cell-type 
enrichment analysis, there was a reduction in the enrichment for most cell types in each 
disorder after conditioning. For SCZ, the previously identified enrichments in pyramidal SS1 
and CA1 cells as well as medium spiny neurons remained significant after conditioning, 
despite also showing evidence for enrichment in BIP. The largest change in enrichment was 
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for serotonergic neurons, indicating that genes highly expressed there are important across all 
psychiatric disorders. 
We provide an analysis framework for conditional cross-disorder analyses using 
summary statistics. Our study was motivated to improve on the SCZ case vs. BIP case 
analyses that utilised PGC cohorts for which both SCZ and BIP genotyped samples were 
available 30, but which necessarily excluded 28% of cases that could not be allocated into 
matched cohorts. They identified 5 SNPs associated at p<5x10-8. We conducted an analysis 
of SCZ conditional on BIP and performed a lookup of those SNPs in the unadjusted and 
adjusted results. All but one (rs200005157) of their associated SNPs were matched directly or 
to an LD proxy (Supplementary Table 7). All show increased statistical significance in the 
conditional analysis. We identified more disorder-specific SNPs (10 specific to SCZ) 
consistent with the larger sample sizes afforded from using summary statistics, highlighting 
that mtCOJO is an efficient method for screening for disorder-specific SNPs for two or more 




There are a number of limitations to our analyses that should be considered. Although 
methods that utilise summary statistics have several advantages, they also depend upon the 
summary statistics being generated accurately. In this instance, all studies have gone through 
the same quality control and analysis pipeline meaning that systematic differences between 
studies are unlikely. It is not clear how misdiagnosis of cases would impact upon the results.  
There are also substantial differences in sample size between the GWAS of different 
disorders, with SCZ and MD having a larger sample size than the other disorders, which may 
disproportionately influence the results. This is shown by most of the significant differences 
in effect sizes between the raw and conditional results being for SCZ. The disorders that have 
the most genome-wide significant SNPs will also have the most accurate estimates of their 
effects on the disorders. As sample sizes increase for some of the other disorders, the results 
for those disorders will become more accurate.  
 In order to reduce the burden of multiple testing in the SMR analysis, we only 
included SNPs that are associated at the genome-wide significant level with gene expression 
or methylation in cis. Relaxing the statistical threshold for inclusion may have identified 
more SNPs with effects on gene expression in brain with the trade-off of increasing the 




In conclusion, our results suggest that mtCOJO is an efficient method for identifying 
variants with disorder-specific effects and they represent a small fraction of variants 
identified for each disorder to date, reflecting the high degree of pleiotropy between 
disorders. Nonetheless, we identify several loci that have evidence of being disorder-specific. 
Further research in human studies should focus on whether the disorder-specific variants 
associate with specific symptoms in mixed clinical populations. 
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Figure 1 – Forest plots for the 4 most significant SNPs in SCZ mtCOJO analysis with larger 
conditional effect sizes 
 









































Table 1. Summary of datasets used and results from conditional GWAS analysis 
 






























SCZ 40,675 64,643 5,471,613 130 Pardinas et al 2018 145 0.01 43 10 15 
BIP 20,352 31,358 9,498,970 16 Stahl et al 2018 BioRxiv 19 0.01 4 3 0 
MD 135,458 344,901 10,468,943 40 Wray et al 2018 44 0.15 15 1 5 
ADHD 19,099 34,194 6,755,648 11 Demontis et al BioRxiv 12 0.05 5 2 3 








Table 2. Estimated SNP-based heritability on the liability scale, genetic correlation and 
LD-score intercepts estimated from LD-score regression 
  SCZ BIP MDD ADHD AUT 
SCZ 0.23 (0.01) 0.21 (0.01) 0.03 (0.01) 0.02 (0.01) 0.008 (0.01) 
BIP 0.67 (0.02) 0.19 (0.01) 0.05 (0.007) 0.03 (0.006) 0.009 (0.008) 
MD 0.36 (0.02) 0.35 (0.02) 0.08 (0.004) 0.10 (0.008) 0.09 (0.008) 
ADHD 0.18 (0.03) 0.15 (0.04) 0.43 (0.03) 0.22 (0.01) 0.35 (0.008) 
AUT 0.23 (0.05) 0.15 (0.05) 0.43 (0.04) 0.36 (0.05) 0.12 (0.01) 
      
LD-score SNP-based heritability on the liability scale and standard error reported on 
diagonal 
 rg and standard error reported below the diagonal   
Bivariate ldsc intercept reported above the diagonal. Value significantly greater than zero 



































Table 3. GSMR estimates of causal effect of each psychiatric disorder on the others with 
conversion to the log odds ratio and liability scales 
Exposure Outcome N SNPs bxy bxy_se bxy_liability OR bxy_pval 
SCZ BIP 111 0.417 0.019 0.417 3.06 5.0E-109 
SCZ MD 111 0.074 0.007 0.109 1.22 4.9E-26 
SCZ ADHD 111 0.054 0.019 0.066 1.16 5.2E-03 
SCZ AUT 111 0.144 0.019 0.144 1.47 2.9E-09 
BIP SCZ 16 0.498 0.039 0.498 3.82 1.6E-37 
BIP MD 16 0.091 0.016 0.134 1.28 2.0E-08 
BIP ADHD 16 0.028 0.043 0.034 1.08 5.2E-01 
BIP AUT 16 0.123 0.046 0.123 1.39 7.4E-03 
MD SCZ 40 0.414 0.059 0.281 2.13 2.7E-12 
MD BIP 40 0.600 0.068 0.408 2.97 1.1E-18 
MD ADHD 40 0.402 0.072 0.339 2.09 2.9E-08 
MD AUT 40 0.463 0.078 0.314 2.33 3.7E-11 
ADHD BIP 13 0.135 0.052 0.109 1.34 8.9E-03 
ADHD MD 13 0.086 0.019 0.102 1.21 9.1E-06 
ADHD SCZ 13 0.156 0.043 0.126 1.40 2.8E-04 
ADHD AUT 11 0.333 0.060 0.269 2.06 2.9E-08 
AUT SCZ 11 0.063 0.041 0.063 1.19 1.3E-01 
AUT BIP 11 0.053 0.057 0.053 1.15 2.9E-01 
AUT MD 11 0.011 0.021 0.016 1.03 5.9E-01 
AUT ADHD 11 0.413 0.062 0.512 3.03 3.60E-11 
        
* Estimates using autism as the exposure used instruments with p < 10E-06 due to lack of 















Table 4. Results for SNPs that were genome-wide significant in the conditional analysis and have larger estimated conditional effect sizes than in 
the original GWAS 
 















SCZ rs3764002 12 108618630 C 0.083 0.012 0.054 0.011 1.94E-12 6.05E-07 WSCD2 
SCZ rs6095357 20 47523865 A -0.069 0.011 -0.048 0.010 1.17E-10 1.21E-06 ARFGEF2 
SCZ rs7790864 7 28478625 A -0.062 0.011 -0.044 0.010 6.33E-09 7.18E-06 CREB5 
SCZ rs1054972 19 1852582 A 0.076 0.013 0.053 0.012 6.42E-09 1.32E-05 KLF16 
SCZ rs2867673 7 71752652 T 0.060 0.010 0.049 0.010 9.44E-09 4.11E-07 CALN1 
SCZ rs6564668 16 79457393 C -0.060 0.010 -0.038 0.010 1.05E-08 7.94E-05 RP11-467I7.1 
SCZ 
rs1192276
5 3 95047279 G -0.060 0.010 -0.044 0.010 1.22E-08 4.36E-06 RPS18P6 
SCZ rs2973038 5 37833781 C 0.066 0.012 0.051 0.011 1.28E-08 1.72E-06 GDNF 
SCZ 
rs1090394
5 10 363275 C 0.057 0.010 0.040 0.010 3.13E-08 3.30E-05 DIP2C 
SCZ 
rs1028293
5 8 38703797 A 0.058 0.011 0.041 0.010 3.97E-08 3.17E-05 TACC1 
SCZ rs6701877 1 174015259 G -0.096 0.014 -0.073 0.013 1.47E-11 2.37E-08 RP11-160H22.3 
SCZ rs7372313 3 135872958 G -0.069 0.010 -0.062 0.010 4.26E-11 1.54E-10 MSL2 
SCZ rs1765142 11 30378559 C 0.065 0.011 0.058 0.010 1.54E-09 1.13E-08 ARL14EP 
SCZ 
rs5564699
3 7 105017864 G -0.062 0.010 -0.053 0.010 2.23E-09 3.83E-08 SRPK2 
SCZ 
rs1504377
60 14 59981768 A 0.131 0.024 0.121 0.022 3.71E-08 4.58E-08 CCDC175 
BIP 
rs1255451
2 9 23352293 T -0.083 0.014 -0.066 0.014 1.55E-09 1.28E-06 ELAVL2 
BIP rs6891181 5 80849101 T -0.081 0.014 -0.075 0.014 1.49E-08 1.27E-07 SSBP2 
BIP 
rs1226891




0 20 47731767 T -0.031 0.005 -0.023 0.005 3.31E-09 3.53E-06 STAU1 
MD rs27732 5 87992576 A 0.034 0.005 0.031 0.005 1.22E-11 1.87E-10 MEF2C 
MD rs1806153 11 31850105 T 0.037 0.006 0.036 0.006 8.78E-10 1.18E-09 RCN1 
MD rs1354115 9 2983774 A 0.029 0.005 0.028 0.005 1.72E-08 2.37E-08 CARM1P1 
MD rs301799 1 8489302 T -0.028 0.005 -0.026 0.005 2.49E-08 4.68E-08 RERE 
ADHD 
rs7864810
4 6 50683009 T 0.136 0.023 0.124 0.025 4.31E-09 3.60E-07 TFAP2D 
ADHD rs2244336 10 8831827 C 0.071 0.013 0.069 0.014 3.81E-08 3.67E-07 ENSG00000270234 
ADHD 
rs1241044
4 1 44188719 A 0.107 0.014 0.106 0.015 4.23E-15 3.85E-13 ST3GAL3 
ADHD 
rs1302383
2 2 215219808 A 0.133 0.020 0.117 0.021 1.23E-11 1.62E-08 SPAG16 
ADHD rs281320 15 47769424 T -0.080 0.013 -0.074 0.013 1.84E-10 3.14E-08 SEMA6D 
AUT 
rs1009910
0 8 10576775 C 0.084 0.014 0.084 0.015 1.20E-09 1.07E-08 SOX7 
 
